Abbott Labs

ABT-N

NYSE:ABT

110.96
0.48 (0.43%)
Abbott Laboratories is a multinational health care company with headquarters in Lake Bluff, Illinois.
More at Wikipedia

Analysis and Opinions about ABT-N

Signal
Opinion
Expert
Chart
PAST TOP PICK
PAST TOP PICK
June 16, 2021
(A Top Pick Jun 24/20, Up 29%) Recently revised guidance by 10-15% of earnings, as they saw a sharp decline in Covid testing. Still growing earnings in double digits. Medical devices and diagnostics are still doing well. Dividend is not high, but increased consistently. She's buying for new clients on this pullback.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
June 16, 2021
(A Top Pick Jun 24/20, Up 29%) Recently revised guidance by 10-15% of earnings, as they saw a sharp decline in Covid testing. Still growing earnings in double digits. Medical devices and diagnostics are still doing well. Dividend is not high, but increased consistently. She's buying for new clients on this pullback.
Christine Poole
Price
$110.580
Owned
Yes
DON'T BUY
DON'T BUY
June 15, 2021

Fine managers and company. They hold the record in raising dividends by 48 straight years. Super stable. They do diagnostics, nutrition, though spun off a business to Abbvie about 8 years ago. They trade in mid-20sx in PE, and grow by a decent 10%. Problem is this high valuation, so he'd look elsewhere in this space, Abbvie, which he owns.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
June 15, 2021

Fine managers and company. They hold the record in raising dividends by 48 straight years. Super stable. They do diagnostics, nutrition, though spun off a business to Abbvie about 8 years ago. They trade in mid-20sx in PE, and grow by a decent 10%. Problem is this high valuation, so he'd look elsewhere in this space, Abbvie, which he owns.

Gordon Reid
Price
$110.655
Owned
No
TOP PICK
TOP PICK
June 8, 2021
Two profit centres are the diagnostic testing and medical devices businesses, accounting for 75% of their operating profit. He's long liked this. Last week, they announced that their Covid-testing business has fallen off with the reopening, so shares sold off. But he sees long-term growth. It trades below 23x earnings in line with peers and market. ABT is defensive with strong growth. Offers good US exposure to healthcare. (Analysts’ price target is $123.33)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
June 8, 2021
Two profit centres are the diagnostic testing and medical devices businesses, accounting for 75% of their operating profit. He's long liked this. Last week, they announced that their Covid-testing business has fallen off with the reopening, so shares sold off. But he sees long-term growth. It trades below 23x earnings in line with peers and market. ABT is defensive with strong growth. Offers good US exposure to healthcare. (Analysts’ price target is $123.33)
Chris Blumas
Price
$108.100
Owned
Yes
DON'T BUY
DON'T BUY
June 4, 2021
It is trading at around 34x earnings. It hasn't done much in the last year. It is where it was last year, maybe 10% up. Compared to the rest of the market, it hasn't moved. Big pharma was out of favour a couple years ago. This has now come back into favour. It is fully valued now. Has had a wonderful run. A little expensive.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
June 4, 2021
It is trading at around 34x earnings. It hasn't done much in the last year. It is where it was last year, maybe 10% up. Compared to the rest of the market, it hasn't moved. Big pharma was out of favour a couple years ago. This has now come back into favour. It is fully valued now. Has had a wonderful run. A little expensive.
David Baskin
Price
$109.350
Owned
No
PAST TOP PICK
PAST TOP PICK
June 3, 2021
(A Top Pick Oct 08/20, Up 0.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $109. To remain disciplined, we recommend covering the balance of the holding. Combined with the previous recommendation to cover 50% of the position, this will result in a net investment gain of 9%.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
June 3, 2021
(A Top Pick Oct 08/20, Up 0.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $109. To remain disciplined, we recommend covering the balance of the holding. Combined with the previous recommendation to cover 50% of the position, this will result in a net investment gain of 9%.
Stockchase Research
Price
$109.000
Owned
_N/A
BUY
BUY
May 20, 2021

ABT vs. MRK Both are great companies. ABT is the leading supplier of products to the medical industry. Merck has incredible products as a global pharmaceutical company. You could hold either.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 20, 2021

ABT vs. MRK Both are great companies. ABT is the leading supplier of products to the medical industry. Merck has incredible products as a global pharmaceutical company. You could hold either.

Bruce Murray
Price
$117.660
Owned
Unknown
BUY
BUY
May 19, 2021

ABT vs. JNJ Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 19, 2021

ABT vs. JNJ Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.

Stan Wong
Price
$116.210
Owned
Unknown
TOP PICK
TOP PICK
May 18, 2021
A diversified US healthcare company in diagnostics, branded pharmaceuticals, nutrition and medical devices. It produces a lot of Covid-testing kits, which has boosted their bottom line. They can maintain double-digit earnings growth based on growth in medical devices. For instance, a diagnostic kit for diabetes (don't need to prick finger) is popular. About 40% of products are sold in emerging markets. They increase their dividend annually, for the past 49 years. Pays a 1.5% dividend. This has pulled back, so buy now. (Analysts’ price target is $133.26)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 18, 2021
A diversified US healthcare company in diagnostics, branded pharmaceuticals, nutrition and medical devices. It produces a lot of Covid-testing kits, which has boosted their bottom line. They can maintain double-digit earnings growth based on growth in medical devices. For instance, a diagnostic kit for diabetes (don't need to prick finger) is popular. About 40% of products are sold in emerging markets. They increase their dividend annually, for the past 49 years. Pays a 1.5% dividend. This has pulled back, so buy now. (Analysts’ price target is $133.26)
Christine Poole
Price
$117.630
Owned
Yes
BUY
BUY
April 16, 2021
They report Tuesday. They've done great work with their Covid test that they will likely hit it out of the park.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 16, 2021
They report Tuesday. They've done great work with their Covid test that they will likely hit it out of the park.
Jim Cramer - Mad Money
Price
$124.350
Owned
Unknown
BUY
BUY
April 14, 2021

Liked BSX better in the past than today. If there were a recession, they'd need more capital. Remains a very fine company as to products. Volumes in medical devices are not recovering as he expected. He owns ABT instead, a diversified player with a very strong balance sheet.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 14, 2021

Liked BSX better in the past than today. If there were a recession, they'd need more capital. Remains a very fine company as to products. Volumes in medical devices are not recovering as he expected. He owns ABT instead, a diversified player with a very strong balance sheet.

David Fingold
Price
$121.680
Owned
Yes
BUY
BUY
March 1, 2021
It has done quite well compared to other healthcare stocks. They have had a lot of regulatory approvals and had strong earnings in Q2-20. In May the sector can do quite well, seasonally. Given its success across its divisions, he would say it is a good stock to hold even before its seasonal period.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
March 1, 2021
It has done quite well compared to other healthcare stocks. They have had a lot of regulatory approvals and had strong earnings in Q2-20. In May the sector can do quite well, seasonally. Given its success across its divisions, he would say it is a good stock to hold even before its seasonal period.
Brooke Thackray
Price
$122.680
Owned
Unknown
BUY
BUY
February 24, 2021
This can still go higher. No need to worry about their diabetes franchise.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 24, 2021
This can still go higher. No need to worry about their diabetes franchise.
Jim Cramer - Mad Money
Price
$122.380
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
February 18, 2021
(A Top Pick Oct 08/20, Up 17.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has achieved its $128 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $97) to the original recommended price level at $109.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 18, 2021
(A Top Pick Oct 08/20, Up 17.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has achieved its $128 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $97) to the original recommended price level at $109.
Stockchase Research
Price
$125.950
Owned
Unknown
BUY
BUY
February 11, 2021
Diversified medical device company. Acquisitions increased leverage, but they've paid it down. Less focused on slower growth business, more on devices. Great quality. Positive results from Covid testing have exceeded estimates.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 11, 2021
Diversified medical device company. Acquisitions increased leverage, but they've paid it down. Less focused on slower growth business, more on devices. Great quality. Positive results from Covid testing have exceeded estimates.
Paul MacDonald
Price
$126.390
Owned
Unknown
BUY
BUY
January 22, 2021
They report Wednesday. They need to mass-produce their quick Covid test that the FDA approved. That said, he expects a beat from them because of progress in Abbott's blood-sugar monitor.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 22, 2021
They report Wednesday. They need to mass-produce their quick Covid test that the FDA approved. That said, he expects a beat from them because of progress in Abbott's blood-sugar monitor.
Jim Cramer - Mad Money
Price
$112.840
Owned
Unknown
Showing 1 to 15 of 147 entries

Abbott Labs(ABT-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 17

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 19

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 19 stock analysts published opinions about ABT-N. 17 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by Christine Poole on 2021-06-16. Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

19 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2021-06-22, Abbott Labs (ABT-N) stock closed at a price of $110.96.